Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion.

Annis MG, Ouellet V, Rennhack JP, L'Esperance S, Rancourt C, Mes-Masson AM, Andrechek ER, Siegel PM.

Breast Cancer Res. 2018 Jan 30;20(1):9. doi: 10.1186/s13058-018-0936-8.

2.

CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling.

Lane D, Matte I, Laplante C, Garde-Granger P, Carignan A, Bessette P, Rancourt C, Piché A.

Mol Cancer. 2016 Sep 9;15(1):58. doi: 10.1186/s12943-016-0542-2.

3.

Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions.

Matte I, Legault CM, Garde-Granger P, Laplante C, Bessette P, Rancourt C, Piché A.

Clin Exp Metastasis. 2016 Dec;33(8):839-852. Epub 2016 Sep 9.

PMID:
27612856
4.

A qualitative study of the current state of heart failure community care in Canada: what can we learn for the future?

Hayes SM, Peloquin S, Howlett JG, Harkness K, Giannetti N, Rancourt C, Ricard N.

BMC Health Serv Res. 2015 Jul 28;15:290. doi: 10.1186/s12913-015-0955-4.

5.

Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.

Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C, Piché A.

BMC Cancer. 2015 Jul 1;15:492. doi: 10.1186/s12885-015-1511-7.

6.

MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signaling.

Giannakouros P, Comamala M, Matte I, Rancourt C, Piché A.

Am J Cancer Res. 2014 Dec 15;5(1):219-30. eCollection 2015.

7.

REM sleep as a potential indicator of hyperarousal in psychophysiological and paradoxical insomnia sufferers.

Pérusse AD, Pedneault-Drolet M, Rancourt C, Turcotte I, St-Jean G, Bastien CH.

Int J Psychophysiol. 2015 Mar;95(3):372-8. doi: 10.1016/j.ijpsycho.2015.01.005. Epub 2015 Jan 14.

PMID:
25596383
8.

Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.

Matte I, Lane D, Laplante C, Garde-Granger P, Rancourt C, Piché A.

Int J Cancer. 2015 Jul 15;137(2):289-98. doi: 10.1002/ijc.29385. Epub 2014 Dec 18.

9.

Transformation of NIH3T3 mouse fibroblast cells by MUC16 mucin (CA125) is driven by its cytoplasmic tail.

Giannakouros P, Matte I, Rancourt C, Piché A.

Int J Oncol. 2015 Jan;46(1):91-8. doi: 10.3892/ijo.2014.2707. Epub 2014 Oct 14.

PMID:
25338620
10.

Role of malignant ascites on human mesothelial cells and their gene expression profiles.

Matte I, Lane D, Bachvarov D, Rancourt C, Piché A.

BMC Cancer. 2014 Apr 24;14:288. doi: 10.1186/1471-2407-14-288.

11.

MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression.

Matte I, Lane D, Boivin M, Rancourt C, Piché A.

BMC Cancer. 2014 Apr 1;14:234. doi: 10.1186/1471-2407-14-234.

12.

Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis.

Lane D, Matte I, Laplante C, Garde-Granger P, Rancourt C, Piché A.

J Ovarian Res. 2013 Nov 23;6(1):82. doi: 10.1186/1757-2215-6-82.

13.

Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis.

Goncharenko-Khaider N, Matte I, Lane D, Rancourt C, Piché A.

Mol Cancer. 2012 Nov 17;11:84. doi: 10.1186/1476-4598-11-84.

14.
15.

Profiling of cytokines in human epithelial ovarian cancer ascites.

Matte I, Lane D, Laplante C, Rancourt C, Piché A.

Am J Cancer Res. 2012;2(5):566-80. Epub 2012 Aug 20.

16.

Targeted ovarian cancer treatment: the TRAILs of resistance.

Khaider NG, Lane D, Matte I, Rancourt C, Piché A.

Am J Cancer Res. 2012;2(1):75-92. Epub 2011 Nov 21.

17.

Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients.

Lane D, Matte I, Rancourt C, Piché A.

BMC Cancer. 2011 May 30;11:210. doi: 10.1186/1471-2407-11-210.

18.

MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis.

Thériault C, Pinard M, Comamala M, Migneault M, Beaudin J, Matte I, Boivin M, Piché A, Rancourt C.

Gynecol Oncol. 2011 Jun 1;121(3):434-43. doi: 10.1016/j.ygyno.2011.02.020. Epub 2011 Mar 21.

PMID:
21421261
19.

Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells.

Comamala M, Pinard M, Thériault C, Matte I, Albert A, Boivin M, Beaudin J, Piché A, Rancourt C.

Br J Cancer. 2011 Mar 15;104(6):989-99. doi: 10.1038/bjc.2011.34. Epub 2011 Feb 15.

20.

The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells.

Goncharenko-Khaider N, Lane D, Matte I, Rancourt C, Piché A.

Oncogene. 2010 Oct 7;29(40):5523-36. doi: 10.1038/onc.2010.288. Epub 2010 Jul 26.

21.

Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes.

Belisle JA, Horibata S, Jennifer GA, Petrie S, Kapur A, André S, Gabius HJ, Rancourt C, Connor J, Paulson JC, Patankar MS.

Mol Cancer. 2010 May 24;9:118. doi: 10.1186/1476-4598-9-118.

22.

Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation.

Lane D, Goncharenko-Khaider N, Rancourt C, Piché A.

Oncogene. 2010 Jun 17;29(24):3519-31. doi: 10.1038/onc.2010.107. Epub 2010 Apr 19.

PMID:
20400979
23.

The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer.

Lane D, Matte I, Rancourt C, Piché A.

J Ovarian Res. 2010 Jan 18;3:1. doi: 10.1186/1757-2215-3-1.

24.

MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells.

Gubbels JA, Felder M, Horibata S, Belisle JA, Kapur A, Holden H, Petrie S, Migneault M, Rancourt C, Connor JP, Patankar MS.

Mol Cancer. 2010 Jan 20;9:11. doi: 10.1186/1476-4598-9-11.

25.

CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.

Boivin M, Lane D, Piché A, Rancourt C.

Gynecol Oncol. 2009 Dec;115(3):407-13. doi: 10.1016/j.ygyno.2009.08.007. Epub 2009 Sep 10.

PMID:
19747716
26.

Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies.

Goodell CA, Belisle JA, Gubbels JA, Migneault M, Rancourt C, Connor J, Kunnimalaiyaan M, Kravitz R, Tucker W, Zwick M, Patankar MS.

J Ovarian Res. 2009 Jun 18;2(1):8. doi: 10.1186/1757-2215-2-8.

27.

Cancer-associated regulation of alternative splicing.

Venables JP, Klinck R, Koh C, Gervais-Bird J, Bramard A, Inkel L, Durand M, Couture S, Froehlich U, Lapointe E, Lucier JF, Thibault P, Rancourt C, Tremblay K, Prinos P, Chabot B, Elela SA.

Nat Struct Mol Biol. 2009 Jun;16(6):670-6. doi: 10.1038/nsmb.1608. Epub 2009 May 17.

PMID:
19448617
28.

Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors.

Ouellet V, Ling TH, Normandin K, Madore J, Lussier C, Barrès V, Bachvarov D, Rancourt C, Tonin PN, Provencher DM, Mes-Masson AM.

BMC Cancer. 2008 Nov 26;8:346. doi: 10.1186/1471-2407-8-346.

29.

Identification of alternative splicing markers for breast cancer.

Venables JP, Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Koh C, Gervais-Bird J, Lapointe E, Froehlich U, Durand M, Gendron D, Brosseau JP, Thibault P, Lucier JF, Tremblay K, Prinos P, Wellinger RJ, Chabot B, Rancourt C, Elela SA.

Cancer Res. 2008 Nov 15;68(22):9525-31. doi: 10.1158/0008-5472.CAN-08-1769.

30.

Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.

Laplante Y, Rancourt C, Poirier D.

Mol Cell Endocrinol. 2009 Mar 25;301(1-2):146-53. doi: 10.1016/j.mce.2008.08.026. Epub 2008 Sep 4.

PMID:
18812208
31.

Multiple alternative splicing markers for ovarian cancer.

Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Gervais-Bird J, Madden R, Paquet ER, Koh C, Venables JP, Prinos P, Jilaveanu-Pelmus M, Wellinger R, Rancourt C, Chabot B, Abou Elela S.

Cancer Res. 2008 Feb 1;68(3):657-63. doi: 10.1158/0008-5472.CAN-07-2580.

32.

Cell detachment modulates TRAIL resistance in ovarian cancer cells by downregulating the phosphatidylinositol 3-kinase/Akt pathway.

Lane D, Cartier A, Rancourt C, Piché A.

Int J Gynecol Cancer. 2008 Jul-Aug;18(4):670-6. Epub 2007 Sep 14.

PMID:
17868340
33.

Nuclear expression of E2F4 induces cell death via multiple pathways in normal human intestinal epithelial crypt cells but not in colon cancer cells.

Garneau H, Alvarez L, Paquin MC, Lussier C, Rancourt C, Tremblay E, Beaulieu JF, Rivard N.

Am J Physiol Gastrointest Liver Physiol. 2007 Oct;293(4):G758-72. Epub 2007 Jul 26.

34.

Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125).

Belisle JA, Gubbels JA, Raphael CA, Migneault M, Rancourt C, Connor JP, Patankar MS.

Immunology. 2007 Nov;122(3):418-29. Epub 2007 Jul 6.

35.

Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells.

Lane D, Robert V, Grondin R, Rancourt C, Piché A.

Int J Cancer. 2007 Sep 15;121(6):1227-37.

36.

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.

Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS.

Mol Cancer. 2006 Oct 26;5(1):50.

37.

Bcl-2 decreases cell proliferation and promotes accumulation of cells in S phase without affecting the rate of apoptosis in human ovarian carcinoma cells.

Bélanger S, Côté M, Lane D, L'Espérance S, Rancourt C, Piché A.

Gynecol Oncol. 2005 Jun;97(3):796-806.

PMID:
15913739
38.

BAG-1 p29 protein prevents drug-induced cell death in the presence of EGF and enhances resistance to anoikis in SKOV3 human ovarian cancer cells.

Pagé V, Côté M, Rancourt C, Sullivan M, Piché A.

Biochem Biophys Res Commun. 2005 Mar 25;328(4):874-84.

PMID:
15707960
39.

Repressed E-cadherin expression in the lower crypt of human small intestine: a cell marker of functional relevance.

Escaffit F, Perreault N, Jean D, Francoeur C, Herring E, Rancourt C, Rivard N, Vachon PH, Paré F, Boucher MP, Auclair J, Beaulieu JF.

Exp Cell Res. 2005 Jan 15;302(2):206-20.

PMID:
15561102
40.

Potentially inappropriate prescriptions for older patients in long-term care.

Rancourt C, Moisan J, Baillargeon L, Verreault R, Laurin D, Grégoire JP.

BMC Geriatr. 2004 Oct 15;4:9.

41.

Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.

Lane D, Cartier A, L'Espérance S, Côté M, Rancourt C, Piché A.

Gynecol Oncol. 2004 Jun;93(3):594-604.

PMID:
15196850
42.

Quantitative assessment of human endometriotic tissue maintenance and regression in a noninvasive mouse model of endometriosis.

Fortin M, Lépine M, Merlen Y, Thibeault I, Rancourt C, Gosselin D, Hugo P, Steff AM.

Mol Ther. 2004 Apr;9(4):540-7.

43.

Tissue transglutaminase triggers oligomerization and activation of dual leucine zipper-bearing kinase in calphostin C-treated cells to facilitate apoptosis.

Robitaille K, Daviau A, Tucholski J, Johnson GV, Rancourt C, Blouin R.

Cell Death Differ. 2004 May;11(5):542-9.

44.
45.
46.

Gene therapy to overcome drug resistance in cancer: targeting key regulators of the apoptotic pathway.

Piché A, Rancourt C.

Curr Gene Ther. 2001 Nov;1(4):317-24. Review.

PMID:
12109059
47.

A role for intracellular immunization in chemosensitization of tumor cells?

Pich A, Rancourt C.

Gene Ther. 1999 Jul;6(7):1202-9. Review.

48.

An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches.

Vanderkwaak TJ, Wang M, Gómez-Navarro J, Rancourt C, Dmitriev I, Krasnykh V, Barnes M, Siegal GP, Alvarez R, Curiel DT.

Gynecol Oncol. 1999 Aug;74(2):227-34.

PMID:
10419736
49.

Interleukin-6 modulated conditionally replicative adenovirus as an antitumor/cytotoxic agent for cancer therapy.

Rancourt C, Piché A, Gomez-Navarro J, Wang M, Alvarez RD, Siegal GP, Fuller GM, Jones SA, Curiel DT.

Clin Cancer Res. 1999 Jan;5(1):43-50.

50.

High-efficacy thymidine kinase gene transfer to ovarian cancer cell lines mediated by herpes simplex virus type 1 vector.

Wang M, Rancourt C, Navarro JG, Krisky D, Marconi P, Oligino T, Alvarez RD, Siegal GP, Glorioso JC, Curiel DT.

Gynecol Oncol. 1998 Nov;71(2):278-87.

PMID:
9826472

Supplemental Content

Loading ...
Support Center